E-4031: Gold-Standard hERG Potassium Channel Blocker for Cardiac Electrophysiology Research

Executive Summary: E-4031 is a potent, selective blocker of the hERG potassium channel (IC50 7.7 nM), used extensively to induce and model proarrhythmic states like QT interval prolongation and torsades de pointes (TdP) in preclinical cardiac safety studies (APExBIO). It alters cardiac action potential duration and electrical restitution in both in vitro and in vivo models. E-4031’s effects are most pronounced in mid-myocardial regions, especially during bradycardia, and its solubility profile enables flexible use in DMSO and ethanol. It is supplied by APExBIO as a ≥98% pure solid, intended exclusively for scientific research. All claims are supported by peer-reviewed publications and manufacturer documentation.

Biological Rationale

ATP-sensitive potassium channels (K_ATP) modulate membrane excitability by coupling cellular metabolism with electrical activity. These channels are distributed in cardiac, skeletal, and smooth muscle, as well as in pancreatic beta cells and the brain (APExBIO). The hERG (human Ether-à-go-go-Related Gene, also known as KCNH2) potassium channel is a critical component of the rapid delayed rectifier potassium current (I_Kr), essential for repolarization of cardiac action potentials. Dysfunction or pharmacological blockade of hERG is a primary mechanism underlying acquired long QT syndrome and the risk of ventricular arrhythmias such as torsades de pointes (TdP).

E-4031 is an established tool for modeling and dissecting these electrophysiological phenomena. Its high selectivity and nanomolar potency make it a benchmark compound in both 2D and 3D cardiac systems (see related article – this article further details experimental parameters and solubility profiles beyond those summarized previously).

Mechanism of Action of E-4031

E-4031 (N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide) is a selective, high-affinity blocker of the hERG potassium channel. Its inhibitory concentration for 50% channel blockade (IC₅₀) is 7.7 nM in standard patch-clamp assays at 22–25°C using physiological buffers (APExBIO).

By blocking hERG/I_Kr, E-4031 delays phase 3 repolarization of the cardiac action potential. This prolongs the QT interval and action potential duration (APD), increases the risk of early afterdepolarizations (EADs), and creates a substrate for TdP. The effect is dose-dependent and reversible upon washout (see related article – the present article adds a detailed discussion of tissue-specific effects and protocol limits).

Evidence & Benchmarks

• E-4031 blocks hERG potassium channels with an IC₅₀ of 7.7 nM (APExBIO product documentation, link).
• It induces QT interval prolongation and TdP in vitro and in vivo, with the largest ARI/QT extension in mid-myocardial regions during bradycardia (APExBIO; see review).
• In patch-clamp studies, E-4031 consistently prolongs action potential duration (APD₉₀) in isolated cardiomyocytes (APExBIO; manufacturer data).
• It reduces upstroke velocity and diastolic depolarization rates, creating a proarrhythmic substrate (APExBIO product sheet, link).
• Animal models confirm dose-dependent inhibition of I_Kr and delayed repolarization at 22–37°C, pH 7.2–7.4 (APExBIO; Sanad et al. 2022).

Applications, Limits & Misconceptions

E-4031 is widely used for:

• Cardiac safety pharmacology: Modeling QT prolongation and TdP risk.
• Dissecting the role of hERG/I_Kr in native tissue and engineered cardiac organoids (related article – this piece extends prior work by detailing integration with high-throughput platforms).
• Evaluating new drug candidates for potential hERG liability.
• Studying metabolic modulation of cardiac excitability via K_ATP channels.

E-4031 is not suitable for clinical or diagnostic use. Its effects are context-dependent and can be modulated by temperature, extracellular ions, and cell type. Data reproducibility depends on solvent, concentration, and storage conditions.

Common Pitfalls or Misconceptions

• Not a pan-K_ATP blocker: E-4031 is highly selective for hERG/I_Kr; it does not block all ATP-sensitive K⁺ channels.
• Not a clinical antiarrhythmic: E-4031 is strictly for research; it is unsafe for therapeutic use.
• Solubility limitations: Poorly soluble in water; must use DMSO (≥103 mg/mL) or ethanol (≥9.66 mg/mL, gentle warming/ultrasound).
• Time- and temperature-sensitive: Solutions are unstable for long-term storage; use freshly prepared aliquots (APExBIO).
• Not a universal arrhythmia model: Only induces arrhythmia in hERG/I_Kr-dependent systems; not effective in all species or models.

Workflow Integration & Parameters

• Formulation: Supplied as a solid (MW 401.52, C₂₁H₂₇N₃O₃S). Store at –20°C. Use blue ice for shipping. Purity ≥98% (APExBIO, SKU B6077).
• Solubility: DMSO ≥103 mg/mL; ethanol ≥9.66 mg/mL with gentle warming/ultrasound. Insoluble in water.
• Recommended concentrations: Typical working range is 1–100 nM for patch-clamp or organoid studies.
• Storage: Solid stable at –20°C. Dissolved aliquots not recommended for long-term storage.

For detailed application in 3D models and translational workflows, see Unlocking the Translational Power of E-4031, which this article updates with expanded solubility and storage data.

For ordering and full technical specifications, refer to the E-4031 product page at APExBIO.

Conclusion & Outlook

E-4031 remains the reference hERG potassium channel blocker for basic and translational cardiac electrophysiology research. Its precise mechanism, robust benchmarks, and well-characterized limitations ensure reproducibility and comparability across studies. Ongoing work integrates E-4031 into high-content and organoid platforms, furthering its utility in proarrhythmic substrate modeling and cardiac safety science.

APExBIO continues to provide validated E-4031 for research use only, enabling rigorous experimental control and data integrity in cardiac electrophysiology.